Sundrug Co.,Ltd. (SDGCF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SDGCF, $ (piyasa değeri 0) fiyatla Healthcare işi olan Sundrug Co.,Ltd.'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 48/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026Sundrug Co.,Ltd. (SDGCF) Sağlık ve Boru Hattı Genel Bakışı
Sundrug Co., Ltd., a Japanese retailer, operates drug and discount stores offering pharmaceuticals, cosmetics, food, and household goods. With a market capitalization of $3.30 billion and a P/E ratio of 14.96, Sundrug distinguishes itself through a broad product portfolio and a widespread store network across Japan.
Yatırım Tezi
Sundrug Co., Ltd. presents a stable investment profile, characterized by its established retail presence and diverse product offerings in the Japanese market. The company's P/E ratio of 14.96 suggests a reasonable valuation compared to its earnings, while a dividend yield of 3.26% offers an income component for investors. A low beta of 0.06 indicates that the stock is less volatile than the overall market. Growth catalysts include potential expansion of its store network and increased demand for healthcare and consumer products in Japan. However, investors may want to evaluate risks such as competition from other retailers and potential changes in consumer spending patterns. The company's profit margin of 3.7% and gross margin of 25.6% reflect its profitability and operational efficiency.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $3.30 billion, reflecting its significant presence in the Japanese retail market.
- P/E ratio of 14.96, indicating a potentially reasonable valuation compared to its earnings.
- Dividend yield of 3.26%, offering an income component for investors.
- Low beta of 0.06, suggesting lower volatility compared to the overall market.
- Gross margin of 25.6%, reflecting its ability to manage production costs and pricing strategies.
Rakipler & Benzerleri
Güçlü Yönler
- Established brand and reputation in the Japanese market.
- Diverse product offerings across drug stores and discount stores.
- Widespread store network providing convenient access for customers.
- Stable financial performance with consistent profitability.
Zayıflıklar
- Relatively low profit margin compared to some competitors.
- Limited international presence.
- Dependence on the Japanese market.
- Potential vulnerability to changes in consumer spending patterns.
Katalizörler
- Ongoing: Expansion of store network in Japan to increase market presence.
- Ongoing: Enhancement of e-commerce platform to cater to online shoppers.
- Upcoming: Potential development of new private label products to improve profitability.
- Ongoing: Strategic alliances and partnerships to expand product offerings and reach.
- Ongoing: Focus on healthcare services to cater to the aging population.
Riskler
- Ongoing: Intense competition from other retailers in the Japanese market.
- Potential: Changes in government regulations affecting the healthcare and retail sectors.
- Potential: Economic downturns impacting consumer spending.
- Potential: Fluctuations in currency exchange rates affecting import costs.
- Potential: Limited financial disclosure due to OTC listing.
Büyüme Fırsatları
- Expansion of Store Network: Sundrug can expand its market presence by opening new stores in underserved regions of Japan. The Japanese retail market is characterized by regional disparities, with some areas having a higher concentration of retail outlets than others. By strategically locating new stores in these underserved regions, Sundrug can tap into new customer bases and increase its overall market share. This expansion strategy could target both urban and rural areas, adapting the store format and product offerings to suit the specific needs of each location. The timeline for this expansion could be phased over the next 3-5 years, with a target of opening 10-15 new stores per year.
- Enhancement of E-commerce Platform: Sundrug can enhance its e-commerce platform to cater to the growing demand for online shopping in Japan. The e-commerce market in Japan has been experiencing rapid growth, driven by increasing internet penetration and changing consumer behavior. By investing in its online platform, Sundrug can reach a wider customer base, offer greater convenience, and improve customer engagement. This enhancement could include features such as personalized recommendations, online ordering and delivery, and mobile app integration. The timeline for this enhancement could be implemented over the next 1-2 years, with a focus on improving user experience and expanding product offerings.
- Development of Private Label Products: Sundrug can develop and expand its range of private label products to improve profitability and differentiate itself from competitors. Private label products typically offer higher profit margins compared to branded products, allowing retailers to improve their overall profitability. By developing its own line of private label products, Sundrug can also create a unique brand identity and build customer loyalty. These products could include pharmaceuticals, health and beauty items, and household goods. The timeline for this development could be phased over the next 2-3 years, with a focus on quality, value, and customer satisfaction.
- Strategic Alliances and Partnerships: Sundrug can form strategic alliances and partnerships with other companies to expand its product offerings and reach new markets. These alliances could include partnerships with pharmaceutical companies, healthcare providers, and other retailers. By collaborating with other companies, Sundrug can leverage their expertise, resources, and distribution networks to enhance its competitive position and drive growth. For example, Sundrug could partner with a pharmaceutical company to develop and market new drugs, or with a healthcare provider to offer integrated healthcare services. The timeline for these alliances could be ongoing, with a focus on identifying mutually beneficial opportunities.
- Focus on Healthcare Services: Sundrug can expand its focus on healthcare services by offering a wider range of services in its drug stores and pharmacies. The demand for healthcare services in Japan is increasing, driven by an aging population and growing awareness of health and wellness. By offering services such as health checkups, medication counseling, and disease management programs, Sundrug can attract new customers and build stronger relationships with existing customers. This expansion could also include the integration of technology, such as telemedicine and remote monitoring, to improve access to healthcare services. The timeline for this expansion could be phased over the next 3-5 years, with a focus on providing high-quality, patient-centered care.
Fırsatlar
- Expansion of e-commerce platform to reach a wider customer base.
- Development of private label products to improve profitability.
- Strategic alliances and partnerships to expand product offerings.
- Focus on healthcare services to cater to the aging population.
Tehditler
- Intense competition from other retailers in the Japanese market.
- Potential changes in government regulations affecting the healthcare and retail sectors.
- Economic downturns impacting consumer spending.
- Fluctuations in currency exchange rates affecting import costs.
Rekabet Avantajları
- Established retail presence in Japan with a widespread store network.
- Diverse product offerings catering to a wide range of consumer needs.
- Strong brand recognition and customer loyalty.
- Efficient supply chain and distribution network.
SDGCF Hakkında
Founded in 1957 and headquartered in Fuchu, Japan, Sundrug Co., Ltd. has evolved into a prominent operator of drug stores and discount stores throughout Japan. The company's business spans a diverse range of products, including pharmaceuticals, cosmetics, home appliances, clothing, car supplies, sports goods, alcoholic beverages, and fresh food. This extensive product offering allows Sundrug to cater to a wide customer base and meet various consumer needs. Sundrug's operations are divided into two primary segments: drug stores and discount stores. The drug stores focus on providing pharmaceutical products, health and beauty items, and over-the-counter medications, often including dispensing pharmacies. The discount stores offer a broader selection of products at competitive prices, attracting customers seeking value and convenience. With a workforce of 6662 employees, Sundrug maintains a significant retail presence across Japan. The company's strategy involves expanding its store network, enhancing its product offerings, and improving operational efficiency to drive growth and profitability. Sundrug's commitment to providing quality products and services has solidified its position in the Japanese retail market.
Ne Yaparlar
- Operates drug stores offering pharmaceuticals, health and beauty products, and over-the-counter medications.
- Manages dispensing pharmacies providing prescription medications and pharmaceutical services.
- Runs discount stores selling a wide range of products, including food, cosmetics, and household goods.
- Offers home appliances, clothing, car supplies, and sports goods in its discount stores.
- Sells alcoholic beverages and fresh food in select locations.
- Provides kerosene and other seasonal products.
İş Modeli
- Generates revenue through the sale of pharmaceutical products and healthcare-related items in its drug stores.
- Earns income from the sale of a diverse range of products in its discount stores.
- Profits from dispensing prescription medications and providing pharmaceutical services in its pharmacies.
- Utilizes a retail network of drug and discount stores to reach customers across Japan.
Sektör Bağlamı
Sundrug Co., Ltd. operates within the competitive Japanese retail market, which includes drug stores, discount stores, and supermarkets. The healthcare and retail sectors in Japan are influenced by factors such as an aging population, increasing healthcare awareness, and evolving consumer preferences. The market is characterized by intense competition, with players like ANSLF, BUGDF, BUHPF, MAHLY, and MEPDF vying for market share. Sundrug differentiates itself through its diverse product offerings and widespread store network. The Japanese retail market is expected to grow steadily, driven by increasing consumer spending and demand for healthcare products and services.
Kilit Müşteriler
- Individuals seeking pharmaceutical products and healthcare-related items.
- Consumers looking for a wide range of products at competitive prices.
- Patients requiring prescription medications and pharmaceutical services.
- Households purchasing everyday essentials and household goods.
Finansallar
Grafik & Bilgi
Sundrug Co.,Ltd. (SDGCF) hisse senedi fiyatı: Price data unavailable
Son Haberler
SDGCF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
SDGCF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
SDGCF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, SDGCF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Hiroshi Sadakata
Unknown
Hiroshi Sadakata is the CEO of Sundrug Co., Ltd., leading a workforce of 6662 employees. Information regarding his detailed career history, educational background, and previous roles is not available in the provided data. As the CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. His leadership is crucial in navigating the competitive Japanese retail market and driving growth for Sundrug.
Sicil: Due to limited information, specific achievements, strategic decisions, and company milestones under Hiroshi Sadakata's leadership cannot be detailed. His tenure and impact on the company's performance require further research and data.
SDGCF OTC Piyasa Bilgileri
The OTC Other tier, where Sundrug Co., Ltd. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as asset size, revenue, or profitability. This lack of regulatory oversight and transparency increases the risk for investors.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases the risk of investing in SDGCF.
- Lower liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud and manipulation.
- Price volatility can lead to significant losses for investors.
- OTC stocks are generally considered riskier than exchange-listed stocks.
- Verify the company's registration and regulatory filings.
- Review available financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Consider the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1957, indicating a long history.
- Sundrug has a significant number of employees (6662), suggesting a substantial operation.
- The company operates a network of drug stores and discount stores across Japan.
- Sundrug has a market capitalization of $3.30 billion, reflecting its size and value.
- The company has a P/E ratio of 14.96 and a dividend yield of 3.26%, suggesting some financial stability.
Yatırımcılar Sundrug Co.,Ltd. (SDGCF) Hakkında Ne Soruyor
SDGCF için değerlendirilmesi gereken temel faktörler nelerdir?
Sundrug Co.,Ltd. (SDGCF) şu anda yapay zeka skoru 48/100, düşük puanı gösteriyor. Temel güçlü yan: Established brand and reputation in the Japanese market.. İzlenmesi gereken birincil risk: Ongoing: Intense competition from other retailers in the Japanese market.. Bu bir finansal tavsiye değildir.
SDGCF MoonshotScore'u nedir?
SDGCF şu anda MoonshotScore'da 48/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
SDGCF verileri ne sıklıkla güncellenir?
SDGCF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler SDGCF hakkında ne diyor?
SDGCF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
SDGCF'a yatırım yapmanın riskleri nelerdir?
SDGCF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Intense competition from other retailers in the Japanese market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
SDGCF'ın P/E oranı nedir?
SDGCF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için SDGCF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
SDGCF aşırı değerli mi, yoksa düşük değerli mi?
Sundrug Co.,Ltd. (SDGCF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
SDGCF'ın temettü verimi nedir?
Sundrug Co.,Ltd. (SDGCF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on CEO's background and track record.
- OTC analysis based on general characteristics of the OTC market due to limited company-specific data.